Redeye gives an initial take on Alelion’s Q3 figures, which was largely in line with our expectations. Sales were somewhat lower, but we do not expect to make any significant full-year revisions, only timing revisions, as the order book for the coming year is known. All focus is now on 2023, following the massive orders Alelion has recently communicated, and on the financing situation, which has been communicated before.